Progenics Pharmaceuticals, Inc., of Tarrytown, N.Y., is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 2 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR (methylnaltrexone bromide) Subcutaneous Injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness.

Research Grants 138 show all


$4.6M
2008

$3.4M
2009

$7.3M
2010

$1.2M
2011

$1.1M
2012

Patents 283show all

  • 100
    A61K - Preparations for medical, dental, or toilet purposes
  • 70
    C07K - Peptides
  • 23
    C12N - Microorganisms or enzymes
  • 21
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 15
    F16L - Pipes
  • 9
    C07D - Heterocyclic compounds
  • 7
    F42B - Explosive charges, e.g. for blasting, fireworks, ammunition
  • 6
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 6
    F21L - Lighting devices or systems thereof, being portable or specially adapted for transportation
  • 6
    F21V - Functional features or details of lighting devices or systems thereof

Clinical Trials 53show all

16Phase 215Phase 19Phase 33Phase 2/Phase 33Phase 45Other

SEC Filings show all


365
8-K

68
10-Q

23
10-K

2
D

1
S-1

Contact Information

777 Old Saw Mill River Road
Tarrytown, NY 10591
United States

Overview

Total FundingEmployeesLast Funding DateStatus
51-100Acquired

SEC Form D Funding Events

DateOfferedSoldType
2013-01-28Indefinite$12,922,374Equity
2006-01-04Unknown Unknown Other (Paper Filing)

Key Executives

  • Mark R. Baker
    Executive Officer, Director
  • Robert J. Israel
    Executive Officer
  • William C. Olson
    Executive Officer
  • Peter J. Crowley
    Director
  • Paul J. Maddon
    Director
  • Charles A. Baker
    Director
  • Kurt W. Briner
    Director
  • Stephen P. Goff
    Director
  • David A. Scheinberg
    Director
  • Nicole S. Williams
    Director